canZero LLC Information

The company’s pipeline includes a strong mix of near-term and long- term value drivers. canZero is currently developing melanoma, breast and prostate cancer vaccines and as the lead program an HPV-SAPN vaccine. Our mono-valent HPV SAPN vaccine has demonstrated excellent preclinical efficacy and our poly- valent vaccine covering all strains of HPV has the potential to replace Gardasil and Cervarix in the future. It offers broad protection against all high-risk HPV strains and incorporates built-in immunopotentiators that are more potent than aluminum-based adjuvants used in current vaccines like Gardasil-9. With the HPV vaccine market growing from $10.8 billion in 2024 to $37 billion by 2032, canZero expects to capture at least 30% of global share. Phase I trials are planned for 2027, with Phase II completion in 2028 and a strategic trade sale in 2029, providing early non-dilutive liquidity to investors. The company’s flagship long-term asset is its personalized VaccinoDrug platform, which integrates tumor sequencing, neoantigen prediction, and rapid SAPN vaccine assembly to create tailor-made cancer immunotherapies. In parallel, canZero is advancing its SAPN-based therapeutic vaccines for melanoma, breast cancer, and prostate cancer, all supported by robust preclinical expression, purification, and nanoparticle refolding data.